Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

被引：3

作者：

Furman, Richard R. ^{[1
]}

Wierda, William G. ^{[2
]}

Schuh, Anna ^{[3
]}

Devereux, Stephen ^{[4
]}

Chaves, Jorge M. ^{[5
]}

Brown, Jennifer R. ^{[6
]}

Hillmen, Peter ^{[7
]}

Martin, Peter ^{[8
]}

Awan, Farrukh T. ^{[9
]}

Stephens, Deborah M. ^{[10
]}

Ghia, Paolo ^{[11
,12
]}

Barrientos, Jacqueline C. ^{[13
]}

Pagel, John M. ^{[14
]}

Woyach, Jennifer ^{[15
]}

Burke, Kathleen ^{[16
]}

Covey, Todd ^{[17
]}

Gulrajani, Michael ^{[18
]}

Hamdy, Ahmed ^{[18
]}

Izumi, Raquel ^{[18
]}

Frigault, Melanie M. ^{[18
]}

Patel, Priti ^{[18
]}

Rothbaum, Wayne ^{[18
]}

Wang, Min Hui ^{[18
]}

O'Brien, Susan M. ^{[19
]}

Byrd, John C. ^{[15
]}

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Oxford, Dept Oncol, Oxford, England

[4] NHS Fdn Trust, Kings Coll Hosp, London, England

[5] Northwest Med Specialties PLLC, Tacoma, WA USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[7] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[8] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA

[9] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[11] Univ Vita Salute San Raffaele, Milan, Italy

[12] IRCCS San Raffaele Sci Inst, Milan, Italy

[13] Hofstra Northwell Sch Med, Hempstead, NY USA

[14] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[15] Ohio State Univ, Columbus, OH 43210 USA

[16] Oncol iMED AstraZeneca, Boston, MA USA

[17] Acerta Pharma, San Francisco, CA USA

[18] Acerta Pharma, San Francisco, CA USA

[19] UC Irvine, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3039

引用

页数：5

共 50 条

[41] LONG-TERM FOLLOW-UP OF A COHORT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH LOW-DOSE ALEMTUZUMAB
Sciume, M.
Vincenti, D.
Reda, G.
Guidotti, F.
Giannarelli, D.
Cortelezzi, A.
HAEMATOLOGICA, 2014, 99 : 585 - 586
[42] ASCEND Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 21 - 22
[43] ACADESINE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTRE PHASE I/II STUDY
van den Neste, E.
Janssens, A.
Gonzalez-Barca, E.
Cazin, B.
Terol, M. J.
Levy, V.
Perez de Oteyza, J.
Saunders, A.
De Elias, M.
Campas, C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 325 - 325
[44] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
Awan, Farrukh T.
Thirman, Michael J.
Patel-Donnelly, Dipti
Assouline, Sarit
Rao, Arati, V
Ye, Wei
Hill, Brian
Sharman, Jeff P.
LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
[45] Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/ Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1 /2 ACE-CL-001 Study
Covey, Todd
Gulranjani, Michael
Cheung, Jean
Bibikova, Elena
Clevenger, Tracy
Krantz, Fanny
Pan, Karen
Yamaguchi, Kyoko
De Jong, Anouk
Van Lith, Bart
Mittag, Diana
Izumi, Raquel
Byrd, John C.
Wierda, William G.
O'Brien, Susan M.
Furman, Richard R.
Kaptein, Allard
BLOOD, 2017, 130
[46] Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study
Woyach, Jennifer A.
Awan, Farrukh T.
Jianfar, Mojgan
Rogers, Kerry A.
Jones, Jeffrey
Covey, Todd
Hamdy, Ahmed
Izumi, Raquel
Patel, Priti
Wang, Min Hui
Byrd, John C.
BLOOD, 2017, 130
[47] A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Barr, Paul M.
Hill, Brian T.
Ma, Shuo
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Zent, Clive S.
BLOOD, 2019, 134
[48] Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Badoux, Xavier C.
Keating, Michael J.
O'Brien, Susan
Wierda, William G.
Faderl, Stefan
Estrov, Zeev
Pasia, Manolo
Lerner, Susan
Sargent, Rachel L.
Kantarjian, Hagop M.
Ferrajoli, Alessandra
BLOOD, 2011, 118 (21) : 448 - 448
[49] Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial
Yang, Shenmiao
Huang, Haiwen
Zhou, Keshu
Zhao, Xielan
Han, Yanqiu
Li, Lindong
Wang, Yujie
Liu, Xiaofeng
Li, Jianyong
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 701 - 712
[50] Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients
Siddiqi, Tanya
Soumerai, Jacob D.
Dorritie, Kathleen A.
Stephens, Deborah M.
Riedell, Peter A.
Arnason, Jon E.
Kipps, Thomas J.
Gillenwater, Heidi H.
Gong, Lucy
Yang, Lin
Ogasawara, Ken
Wierda, William G.
BLOOD, 2020, 136

← 1 2 3 4 5 →